Pharmaron Acquires Majority Stake in SNBL CPC
Acquisition expands Pharmaron’s integrated offerings to clinical development phase
Beijing, February 28, 2017 — Pharmaron, a fully integrated contract research organization offering R&D services to the life sciences industry, today announced that it has signed a definitive agreement under which Pharmaron will acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (“SNBL CPC”) in Baltimore, Maryland, USA. This clinical center is a leading provider of moderate and highly complex Phase I/II clinical development services for the life sciences sector. Current shareholder Shin Nippon Biomedical Laboratories, Ltd. (SNBL) (TSE:2395) will retain a minority stake in the business following the transaction.
SNBL CPC is a full-service clinical CRO located on the campus of the University of Maryland BioPark. Since its inception in 2005, over 200 studies have been completed in the purpose-built, clinical pharmacology unit. Many of these completed clinical studies have been submitted in support of global regulatory filings for drug approval for marketing of both small and large molecules. This strategic acquisition allows Pharmaron to be one-step closer to offering a full spectrum of R&D services. Addition of this capability to the Pharmaron Group naturally complements and expands Pharmaron’s existing drug R&D services, further consolidating the clinical development capabilities, through synergistic integration with recently acquired radiolabelled science capabilities, including Quotient Bioresearch’s clinical metabolism in the UK and Xceleron’s AMS-based 14C-microtracer technology in the USA.
Mr. Larry Lou, President and COO of Pharmaron commented: “We are delighted to have SNBL CPC join the Pharmaron Group. This is an important milestone for Pharmaron. Once integrated and further developed, the new clinical platform will fuel the corporate engine for business growth in a sustainable manner. This is another testimony of our determination to fully realize our mission to support our clients’ success in discovery, development and commercialization of important medicines and fulfill our vision to be a global leading organization in the life sciences service industry.”
Dr. Ryoichi Nagata, Chairman and CEO of SNBL commented: “The mission of SNBL CPC has been to offer complex and innovative clinical pharmacology services in close proximity to leading university medical centers. Through this transaction, we look forward to seeing future growth of CPC as part of Pharmaron Group.”
The financial terms of the transaction are not being disclosed.
Teneo Capital served as financial advisor to Pharmaron; O’Melveny & Myers LLP served as Pharmaron’s legal advisor. SC&H Capital served as financial advisor to SNBL; Miles & Stockbridge P.C. served as legal advisor to SNBL.
About Pharmaron
Pharmaron is a private, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical analytical sciences to chemical & pharmaceutical development. With over 4,000 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. www.www.pharmaron.com
About SNBL CPC
SNBL CPC is a clinical pharmacology facility located in the University of Maryland BioPark in Baltimore, Maryland, USA. The state of the art facility and equipment is bolstered by a vibrant research community. SNBL CPC specializes in complex Phase I-II trials, including TQT/Phase 1 QT de-risking, first-In-human (FIH), Japanese Bridging and Phase II Proof of Concept (POC) studies in therapeutics areas including immunology/infectious disease, neurology, respiratory, dermatology and more. SNBL CPC conducts clinical trials from multiple sectors, including biopharmaceutical and biotech industry, academia, and the government. SNBL CPC offers full service support of clinical trials through its in-house resources, expert partners from surrounding universities and practices. Proximity and the agreements that SNBL CPC has developed with the University of Maryland, Baltimore and Johns Hopkins University makes this facility best of its kind.
For further information please contact:
Ashok Tehim, Senior VP, Strategy, Tel: +1 201 312 5754, ashok.tehim@pharmaron.com
Ellen Cabral, Director, Global Marketing, Tel: +1 617 901 2216, ellen.cabral@pharmaron.com
康龙化成宣布收购SNBL临床药理试验中心的绝对控股权
旨在增强其临床研发服务能力
北京，2017年2月28日讯—康龙化成宣布收购SNBL临床药理中心（SNBL CPC）的绝对控股权。该临床中心位于美国马里兰州的巴尔的摩市，为生物医药领域提供复杂的I期和II期临床试验服务，处业内领先水平。根据协议，SNBL（股票代码为TSE：2395）仍将持有少量CPC的股权。
SNBL CPC拥有独立的、专业设计的临床试验设施，提供全方位的I期和II期临床开发服务。该中心成立于2005年，位于马里兰大学生命科技园内，至今已完成超过200例各类生物药和小分子化学药的临床试验，用于新药在全球各地的审批上市。临床试验服务能力是康龙化成现有新药研发服务能力的自然延伸和拓展，并和公司近期收购的基于放射性技术临床代谢服务的英国Quotient Bioresearch公司和基于加速型质谱（AMS）的14C标记微量示踪物（14C microtracers）技术的美国Xceleron公司形成良好的协同效应。此次战略性收购，将大力增强康龙化成的临床开发服务能力，加速其全方位新药研发服务建设。
康龙化成总裁兼首席运营官楼小强先生表示：“欢迎SNBL CPC加入康龙化成大家庭。这在康龙化成发展史上具有里程碑式的意义。通过业务整合及进一步开发，该临床服务平台将为我们企业的持续发展注入强劲动力。此举再次证明了我们致力于成为全球新药研发服务行业领军企业的决心，我们将始终坚持我们的企业使命：以最高水平的研发服务，帮助伙伴们成功开发新药。”
SNBL董事长兼CEO Ryoichi Nagata博士表示：“ SNBL CPC的使命是通过设立在各一流大学医学中心就近的临床开发服务平台，为全球生物医药领域提供高难度的、富有创造性的临床药理服务。通过此次交易，我们期待CPC融入康龙化成大家庭，并取得进一步发展。”
双方并未透露此次交易的商业细节。
此次交易，康龙化成的财务顾问为Teneo 资本，法律顾问为美迈斯律师事务所；SC&H Capital和Miles & Stockbridge P.C.分别担任SNBL的财务顾问和法律顾问。
关于康龙化成
康龙化成新药技术有限公司（非上市企业），成立于2003年，是国际领先的生命科学研发服务企业。公司宗旨为“以最高水平的研发服务，帮助伙伴们成功开发新药，降低新药研发成本，提高新药研发效率”。经过多年发展，康龙化成打造了全方位的药物研发一体化平台，贯穿合成与药物化学、生物学、药物代谢及药代动力学、药理学、药物安全性评价、放射标记代谢、临床分析、工艺研发、GMP生产及制剂研发服务等各个领域，提供包括靶标探索与靶标验证、先导化合物发现，先导化合物优化、临床前候选药物筛选、新药临床前及临床开发和新药申报等一体化研发和开发服务。康龙化成在中国、美国、英国均有运营实体，拥有4000多名员工，一流的人才队伍，高质量的研发服务，获得了业界的广泛认可，与北美、欧洲、日本和中国的各医药公司/机构保持着长期、稳固的合作关系。详情请访问公司网站：www.www.pharmaron.com
关于SNBL CPC
SNBL CPC 是SNBL旗下的临床药理中心，位于美国马里兰州巴尔的摩市的马里兰大学生命科技园内，拥有国际一流的实验设施和充满活力的科研人员。专注于高难度的I期和II期临床开发服务，包括心脏毒性临床评价（TQT）、首次应用于人体试验 (FIH)、日本桥接试验（Japanese Bridging）和其它富有挑战性的试验，涉及免疫学、传染病、神经病学、呼吸、皮肤病等。与生物医药企业、学院和政府等生命科学领域相关机构建立广泛合作关系。得益于马里兰大学、美国约翰霍普金斯大学等高等学府的有力支持和各类内部资源的有效利用，使之成为最为出色的临床药理试验中心之一。
详情请联系：
Ashok Tehim博士，高级副总裁，企业战略，Tel: +1 201 312 5754, ashok.tehim@pharmaron.com
Ellen Cabral女士， 全球市场营销总监，Tel: +1 617 901 2216, ellen.cabral@pharmaron.com